46372 Federal Register / Vol. 62, No. 169 / Tuesday, September 2, 1997 / Notices

The Proposed Action is the

construction and operation of two water

pipelines and supporting pumping

facilities. These facilities are required to

supplement the Contra Costa Canal and

provide adequate water transmission

capacity to meet the projected demand

through the year 2020.

The purpose of the meeting is to

receive comments regarding the

appropriate scope of the DEIS. CCWD

staff will make a brief presentation to

describe the proposed project, its

purpose and need, alternative pipeline

alignments, and scenarios for

construction and operation. The public

may comment on the environmental

issues to be addressed in the DEIS. If

necessary due to large attendance,

comments will be limited to 5 minutes

per speaker. Written comments will also

be accepted by the District through

September.

DATES: A scoping meeting is scheduled

for the project on Saturday, September

18, 1997, at 7:00 p.m.

ADDRESSES: The scoping meeting will be

held at the Bay Point Ambrose

Community Center, 3105 Willow Pass

Road, Bay Point, California. Information

on the scoping meeting and the DEIS

may be obtained from Mr. Steve

Edmondson, Bureau of Reclamation,

South-Central California Area Office,

2666 North Grove Industrial Drive, Suite

106, Fresno, CA 93727.

FOR FURTHER INFORMATION CONTACT: Mr.

Steve Edmondson, Bureau of

Reclamation, (209) 487–5049; or Ms.

Christina Ko Hartinger, Contra Costa

Water District, (510) 688–8335.

SUPPLEMENTARY INFORMATION: CCWD’s

MPP Project involves the following

improvements:

1. Multi-Purpose Pipeline. The multipurpose pipeline is a capacity

improvement project for meeting year

2020 system demands of CCWD’s raw

water system. The MPP would

supplement the capacity of the Contra

Costa Canal (which carries raw water)

with a treated water pipeline extending

approximately 22 miles from CCWD’s

Randall-Bold Water Treatment Plant in

Oakley, east to CCWD’s Treated Water

Service Area in Concord. The MPP

would terminate near CCWD’s Bollman

Water Treatment Plant near Concord.

This new treated water pipeline

paralleling the canal would free up

canal capacity for raw water

transmission. Under normal operations,

the MPP would convey treated water

westward to CCWD’s Treated Water

Service Area. In an emergency, the MPP

could also carry treated water eastward

from CCWD’s Bollman Water Treatment

Plant. The 25-million-gallons-per-day

(mgd) pipeline would be 36 inches in

diameter and approximately 22 miles

long. CCWD is evaluating several

pipeline route alternatives including:

the canal right-of-way, local streets, and

an active railroad corridor.

2. Raw Water Pipeline. The MPP

Project also includes approximately 4

miles of 36-inch raw water pipeline (36

mgd) bypassing canal reach 4 from

downstream of the Neroly Blending

Facility to the canal near Antioch. The

raw water pipeline could be installed

parallel and adjacent to the MPP

pipeline. The raw water pipeline is

sized to meet the year 2020 canal

demands through the existing tunnel

segment within canal reach 4.

3. Treated Water Pump Station. The

MPP Project includes a proposed 25-

mgd pump station at the Randall-Bold

Water Treatment Plant to pump treated

water from the plant through the multipurpose pipeline. No treatment plant

capacity improvements are required for

the MPP.

4. Raw Water Pump Station. The MPP

Project includes a 36-mgd raw water

pump station that would be located

downstream of the Neroly Blending

Facility and upstream of the tunnel. The

pump station would pump raw water

from the Canal through the raw water

pipeline.

5. Canal Gate Improvements and

Neroly Blending Facility Improvements.

The MPP Project includes modifications

to six of the seven active check

structures along the canal between

pumping plant No. 4 and Mallard

Reservoir at Bollman Water Treatment

Plant. At each check structure, CCWD

would install motorized gates that could

be opened during periods of high flow

rates, thereby increasing canal capacity.

The Neroly Blending Facility (an incanal facility to blend Delta water and

water from the Los Vaqueros Reservoir)

would be expanded by widening the

canal or raising the sides.

6. Back-up Power for MPP Treated

Water Pump Station. As part of the MPP

Project, the District would install an

emergency generator for the firm

capacity (four 1,000-horsepower pumps)

at the MPP treated water pump station.

7. MPP Enhancements. The District

would construct emergency connections

from the MPP to the canal and to the

shortcut pipeline, thereby allowing the

MPP to deliver water to functional

portions of the canal that may be

disconnected from eastern supply

sources during an emergency such as an

earthquake. In addition, these

connections could be used to

temporarily supply treated water to the

canal while portions of the canal are out

of service for maintenance.

These actions will be evaluated in

accordance with the legislative

requirements of NEPA and other

relevant regulations. CCWD is preparing

an environmental impact report (EIR) on

the project, pursuant to the California

Environmental Quality Act (CEQA).

Dated: August 20, 1997.

William Luce,

Area Manager, South-Central California Area

Office.

[FR Doc. 97–23132 Filed 8–29–97; 8:45 am]

BILLING CODE 4310–94–U

INTERNATIONAL DEVELOPMENT

COOPERATION AGENCY

Overseas Private Investment

Corporation

Submission for OMB Review;

Comment Request

AGENCY: Overseas Private Investment

Corporation, IDCA.

ACTION: Request for comments.

SUMMARY: Under the provisions of the

Paperwork Reduction Act (44 U.S.C.

Chapter 35), Agencies are required to

publish a Notice in the Federal Register

notifying the public that the Agency is

preparing an information collection

request for OMB review and approval

and to request public review and

comment on the submission. Comments

are being solicited on the need for the

information, its practical utility, the

accuracy of the Agency’s burden

estimate, and on ways to minimize the

reporting burden, including automated

collection techniques and uses of other

forms of technology. The proposed form

under review is summarized below.

DATES: Comments must be received on

or before November 3, 1997.

ADDRESSES: Copies of the subject form

and the request for review prepared for

submission to OMB may be obtained

from the Agency Submitting Officer.

Comments on the form should be

submitted to the Agency Submitting

Officer.

FOR FURTHER INFORMATION CONTACT:

OPIC Agency Submitting Officer: Lena

Paulsen, Manager, Information Center,

Overseas Private Investment

Corporation, 1100 New York Avenue,

N.W., Washington, D.C. 20527; 202/

336–8565.

SUMMARY OF FORM UNDER REVIEW:

Type of Request: Revised form.

Title: Application for Political Risk

Investment Insurance—Contractors and

Exporters Program.

Form Number: OPIC–81.
Federal Register / Vol. 62, No. 169 / Tuesday, September 2, 1997 / Notices 46373

Frequency of Use: Once per investor

per project.

Type of Respondents: Business or

other institutions (except farms);

individuals.

Standard Industrial Classification

Codes: All.

Description of Affected Public: U.S.

companies or citizens investing

overseas.

Reporting Hours: 4 hours per project.

Number of Responses: 15 per year.

Federal Cost: $300 per year.

Authority for Information Collection:

Sections 231, 234(a), 239(d), and 240A

of the Foreign Assistance Act of 1961,

as amended.

Abstract (Needs and Uses): The

application for the contractors and

exporters program is the principal

document used by OPIC to determine

the investor’s and project’s eligibility,

assess the environmental impact and

developmental effects of the project,

measure the economic effects for the

United States and the host country

economy, and collect information for

underwriting analysis.

Dated: August 26, 1997.

James R. Offutt,

Assistant General Counsel, Department of

Legal Affairs.

[FR Doc. 97–23137 Filed 8–29–97; 8:45 am]

BILLING CODE 3210–01–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[DEA # 167P]

Controlled Substances: Proposed

Aggregate Production Quotas for 1998

AGENCY: Drug Enforcement

Administration (DEA), Justice.

ACTION: Notice of proposed aggregate

production quotas for 1998.

SUMMARY: This notice proposes initial

1998 aggregate production quotas for

controlled substances in Schedules I

and II of the Controlled Substances Act.

DATES: Comments or objections must be

received on or before October 2, 1997.

ADDRESSES: Send comments or

objections to the Administrator, Drug

Enforcement Administration,

Washington, DC 20537, Attn.: DEA

Federal Register Representative (CCR).

FOR FURTHER INFORMATION CONTACT:

Frank L. Sapienza, Chief, Drug and

Chemical Evaluation Section, Drug

Enforcement Administration,

Washington, DC 20537, Telephone:

(202) 307–7183.

SUPPLEMENTARY INFORMATION: Section

306 of the Controlled Substances Act

(21 U.S.C. 826) requires that the

Attorney General establish aggregate

production quotas for each basic class of

controlled substance listed in Schedules

I and II. This responsibility has been

delegated to the Administrator of the

DEA by § 0.100 of Title 28 of the Code

of Federal Regulations. The

Administrator, in turn, has redelegated

this function to the Acting Deputy

Administrator pursuant to § 0.104 of

Title 28 of the Code of Federal

Regulations.

The quotas are to provide adequate

supplies of each substance for: (1) The

estimated medical, scientific, research,

and industrial needs of the United

States; (2) lawful export requirements;

and (3) the establishment and

maintenance of reserve stocks.

In determining the proposed 1998

aggregate production quotas, the Acting

Deputy Administrator considered the

following factors; (1) Total actual 1996

and estimated 1997 and 1998 net

disposals of each substance by all

manufacturers; (2) estimates of 1997

year-end inventories of each substance

and of any substance manufactured

from it and trends in accumulation of

such inventories; (3) product

development requirements of both bulk

and finished dosage form

manufacturers; (4) projected demand as

indicated by procurement quota

applications filed pursuant to § 1303.12

of Title 21 of the Code of Federal

Regulations and (5) other pertinent

information.

Pursuant to § 1303.23(c) of Title 21 of

the Code of Federal Regulations, the

Acting Deputy Administrator of the

DEA will, in early 1998, adjust aggregate

production quotas and individual

manufacturing quotas allocated for the

year based upon 1997 year-end

inventory and actual 1997 disposition

data supplied by quota recipients for

each basic class of Schedule I or II

controlled substance.

Therefore, under the authority vested

in the Attorney General by section 306

of the Controlled Substances Act of

1970 (21 U.S.C. 826), delegated to the

Administrator of the DEA by § 0.100 of

Title 28 of the Code of Federal

Regulations, and redelegated to the

Acting Deputy Administrator pursuant

to § 0.104 of Title 28 of the Code of

Federal Regulations, the Acting Deputy

Administrator hereby proposes that the

aggregate production quotas for 1998 for

the following controlled substances,

expressed in grams of anhydrous acid or

base, be established as follows:

Basic class Proposed

1998 quotas

Schedule I

2,5-Dimethoxyamphetamine ................................................................................................................................................................ 15,000,100

2,5-Dimethoxy-4-ethylamphetamine (DOET) ....................................................................................................................................... 2

3-Methylfentanyl ................................................................................................................................................................................... 14

3-Methylthiofentanyl ............................................................................................................................................................................. 2

3,4-Methylenedioxyamphetamine (MDA) ............................................................................................................................................. 25

3,4-Methylenedioxy-N-ethylamphetamine (MDEA) .............................................................................................................................. 30

3,4-Methylenedioxymethamphetamine (MDMA) .................................................................................................................................. 20

3,4,5-Trimethoxyamphetamine ............................................................................................................................................................ 2

4-Bromo–2,5-Dimethoxyamphetamine ................................................................................................................................................ 2

4-Bromo–2,5-Dimethoxyphenethylamine (2-CB) ................................................................................................................................. 2

4-Methoxyamphetamine ....................................................................................................................................................................... 100,100

4-Methylaminorex ................................................................................................................................................................................. 2

4-Methyl–2,5-Dimethoxyamphetamine (DOM) .................................................................................................................................... 2

5-Methoxy–3,4-Methylenedioxyamphetamine ..................................................................................................................................... 2

Acetyl-alpha-methylfentanyl ................................................................................................................................................................. 2

Acetylmethadol ..................................................................................................................................................................................... 7

Allylprodine ........................................................................................................................................................................................... 2

Alpha-acetylmethadol ........................................................................................................................................................................... 7

Alpha-ethyltryptamine .......................................................................................................................................................................... 2